BioNTech SE (BNTX) Stock: Price, Forecast & Analyst Target
BioNTech SE (BNTX) — MoonshotScore 52/100 (Fair band), calculated Oct 5, 2026. Price $96.90 (+0.05%), as of the Oct 2, 2026 trading session; market cap $24.3B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
BioNTech SE · BNTX · NASDAQ · Healthcare · Biotechnology
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · BioNTech SE (BNTX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality and a strained balance sheet, though growth is only middling. Business Quality: Thin; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Rising.
- quarterly revenue $118M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 6 of 8
- Altman Z 6.82 · Piotroski F 2
Holding back: balance-sheet strain
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 52 | Fair | |
| 52 | Fair | |
| 52 | Fair | |
| 52 | Fair | |
| 51 | Fair | |
| 51 | Fair |
The score was 52 in the stored Oct 4, 2026 snapshot and remains 52 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +2; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $96.90 | |
| Change on the day | +0.05% | |
| 52-week range | $79.52 – $124.00 | |
| Market capitalisation | $24.3B | |
| Shares traded on the day | 696.0K | |
| Beta (volatility vs the S&P 500) | 1.29 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for BioNTech SE (BNTX): Split View
40/100 · CCouncil is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
2 lenses, 2 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the BNTX film — every key number, told as a short cinematic story
~2 min · open the film
What is BioNTech SE (BNTX), and what does it report?
Short answer · as of
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. BioNTech SE (BNTX) is listed on NASDAQ. BioNTech SE (BNTX) is classified as Healthcare / Biotechnology. SEC filing business address: AN DER Goldgrube 12, Mainz, 2M, 55131. It employs 7,807 people and is led by Ugur Sahin. In Q2 FY2026 it reported revenue of $118M and net income of -$918M. The market values it at $24.3B.
What do the latest results show for BioNTech SE (BNTX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $118M. Against analyst estimates the company has EPS beat 6 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $120.60M Aug 4, 2026
- Latest report · revenue estimate
- $180.18M Aug 4, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $120.60M | $180.18M | −$3.7003 | −$2.3983 |
| May 5, 2026 | $136.45M | $207.42M | −$2.4263 | −$2.5384 |
| Mar 10, 2026 | $1.07B | $902.33M | −$1.4447 | −$0.2200 |
| Nov 3, 2025 | $1.78B | $843.68M | −$0.1400 | −$1.1172 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $118M | -$918M | -$3.62 (diluted) |
| Q1 FY2026 | $134M | -$605M | -$2.39 (diluted) |
| Q4 FY2025 | $1.01B | -$338M | -$1.38 (diluted) |
| Q3 FY2025 | $1.70B | -$32M | -$0.13 (diluted) |
What are the financial strengths and risks for BioNTech SE (BNTX)?
Short answer
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 6.82 · Piotroski F 2. Trailing ratios: ROE -6.7% · ROA -5.9% · current ratio 8.80 · earnings yield -6.5% · free-cash-flow yield 3.6%.
Data-derived red flags
- Negative return on equity (-6.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at BioNTech SE (BNTX)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026. Current published price targets run low $96.00 · high $140.00 · consensus $121.83 · median $127.00 against a quoted price of $96.90 (as of Oct 2, 2026).
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
Checked against the records this page reads, on the dates shown above.
How does BioNTech SE compare with its peers?
Short answer
BioNTech SE's score ranks 5th of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $85.36 Oct 2, 2026 | $32.2B | 96 5-pillar Oct 5, 2026 | |
| $23.92 Oct 2, 2026 | $23.4B | 74 5-pillar Oct 5, 2026 | |
| $219.88 Oct 2, 2026 | $32.5B | 67 5-pillar Oct 5, 2026 | |
| $39.53 Oct 2, 2026 | $46.0B | 66 5-pillar Oct 5, 2026 | |
| BioNTech SE (BNTX) — this page | $96.90 | $24.3B | 52 |
| $410.35 Oct 2, 2026 | $58.8B | 38 5-pillar Oct 5, 2026 | |
| $115.30 Date unavailable | $23.4B | — Model unavailable | |
| $57.16 Date unavailable | $25.3B | — Model unavailable | |
| $541.70 Date unavailable | $23.0B | — Model unavailable | |
| $219.72 Date unavailable | $29.4B | — Model unavailable | |
| $58.39 Date unavailable | $14.7B | — Model unavailable | |
| $143.18 Date unavailable | $14.4B | — Model unavailable | |
| $227.87 Date unavailable | $14.2B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $96.00 – $140.00
- Consensus target
- $121.83
- Median target
- $127.00
Consensus record · Captured .
Measured against a quoted price of $96.90 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 2, 2026
- Transactions
- 32
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 22
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 18.6% Period end Jun 30, 2026
- Previous quarter · ownership
- 18.8% Prior to period end Jun 30, 2026
- Reporting holders
- 318 Period end Jun 30, 2026
- Previous quarter · holders
- 302 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 7,571,805 |
| Primecap Management Co/Ca/ | 3,772,031 |
| Dodge & Cox | 3,677,591 |
| Flossbach Von Storch AG | 2,226,138 |
| T. Rowe Price Investment Management, INC. | 2,065,456 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about BioNTech SE (BNTX)?
Common Questions About BNTX (Healthcare)
These answers are editorial: 1 of these 9 answers is drawn from the BNTX research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BNTX?
BNTX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is BNTX a good stock to buy?
Stock Expert AI does not rate BNTX buy, sell or hold. BioNTech SE carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BNTX stock price today?
The last price recorded on this page for BioNTech SE (BNTX) is $96.90, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BNTX price target?
The analyst consensus price target for BioNTech SE (BNTX) is $121.83 (range $96.00 to $140.00, median $127.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about BNTX stock?
Analysts generally view BioNTech SE as a key player in the biotechnology sector, particularly due to its innovative mRNA technology and strong pipeline.
What are the key factors to evaluate for BNTX?
BioNTech SE (BNTX) holds a MoonshotScore in the moderate range. Analysts target $121.83 (+26%). No dividend yield as the company reinvests profits into R&D for future growth. Not financial advice.
How frequently does BNTX data refresh on this page?
BNTX's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BNTX's recent stock price performance?
BioNTech SE (BNTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative mRNA technology with proven efficacy in vaccines. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BNTX overvalued or undervalued right now?
BioNTech SE (BNTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $121.83 (+26%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (55 figures)
The 55 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | AN DER Goldgrube 12, Mainz, 2M, 55131 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "An der Goldgrube 12, Mainz, RP, 55131, DE". |
FMP — 45 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $96.90 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T18:44:45.365Z. | |
px.change | Change on the day | +0.05% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $24.3B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T18:44:43.939Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.05 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $118M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 696.0K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.29 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2836 — Biological Products, (No Diagnostic Substances). | |
id.employees | Employees | 7,807 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Ugur Sahin | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q2 FY2026 | -$918M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
id.founder | Founder named in the filing | Ozlem Tureci — Co-Founder, Chief Medical Officer & Member of Management Board | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $120.60M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $180.18M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | −$3.7003 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | −$2.3983 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_actual | Revenue · reported — report date 2026-05-05 | $136.45M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_estimated | Revenue · estimate — report date 2026-05-05 | $207.42M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | −$2.4263 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | −$2.5384 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-10.revenue_actual | Revenue · reported — report date 2026-03-10 | $1.07B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-10.revenue_estimated | Revenue · estimate — report date 2026-03-10 | $902.33M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-10.eps_actual | EPS · reported — report date 2026-03-10 | −$1.4447 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-10.eps_estimated | EPS · estimate — report date 2026-03-10 | −$0.2200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_actual | Revenue · reported — report date 2025-11-03 | $1.78B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_estimated | Revenue · estimate — report date 2025-11-03 | $843.68M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_actual | EPS · reported — report date 2025-11-03 | −$0.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_estimated | EPS · estimate — report date 2025-11-03 | −$1.1172 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $96.00 · high $140.00 · consensus $121.83 · median $127.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $96.00 – $140.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $121.83 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $127.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 32 transactions · 0 purchases, 22 sales, 10 other transactions · 6 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 2, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 18.6% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 18.8% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 318 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 302 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 7,571,805 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Primecap Management Co/Ca/ — shares in provider snapshot | 3,772,031 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Dodge & Cox — shares in provider snapshot | 3,677,591 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Flossbach Von Storch AG — shares in provider snapshot | 2,226,138 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | T. Rowe Price Investment Management, INC. — shares in provider snapshot | 2,065,456 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 6.82 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $79.52 – $124.00 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -6.7% · ROA -5.9% · current ratio 8.80 · earnings yield -6.5% · free-cash-flow yield 3.6% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($120.60M) with the recorded estimate ($180.18M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$3.7003) with the recorded estimate (−$2.3983) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 52 of 100 · Fair · pillars 37 / 28 / 62 / 48 / 69 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 52 (stored snapshot Oct 4, 2026) → 52 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-05-05.revenue_actual,earn.history.depth.2026-05-05.revenue_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-03-10.revenue_actual,earn.history.depth.2026-03-10.revenue_estimated,earn.history.depth.2026-03-10.eps_actual,earn.history.depth.2026-03-10.eps_estimated,earn.history.depth.2025-11-03.revenue_actual,earn.history.depth.2025-11-03.revenue_estimated,earn.history.depth.2025-11-03.eps_actual,earn.history.depth.2025-11-03.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.
ETFs that hold BNTX
Funds in our ETF coverage that list BNTX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Genomics Immunology and Healthcare ETF (IDNA) | 3.89% | |
| Global X - Genomics & Biotechnology ETF (GNOM) | 3.87% | |
| WisdomTree BioRevolution Fund (WDNA) | 2.41% |